SMARCD3 depletion results in lower proliferation rates, increased endoreplication and unresolved DNA damage, suggesting its potential role as a tumour suppressor and a specific prognostic biomarker for breast cancer [180,181]. Here, SMARCD3 is linked to breast carcinoma.